The nation of Zimbabwe has declined a significant US health deal valued at 367 million US dollars (272 million pounds) over five years due to the United States' demand for sensitive information.
This move came to light following a official document from December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "unbalanced".
An official representative later clarified that the US was requesting biological samples for scientific study and commercial gain but was not willing to share the benefits from future treatments.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more talks to find a agreement acceptable to all parties so the country's vital HIV treatment initiative can proceed.
Broader Background
This development comes after a comparable case in Kenya, where a high court blocked a related health funding agreement after concerns were filed about the safety of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral agreements to boost openness and responsibility.
According to reports, 16 African countries have so far agreed to similar health pacts, constituting over $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment via American-funded initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, without any equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that could result from that provided information," Mangwana explained.
"In essence, our country would supply the basic resources for scientific discovery with no certainty that the end products would be available to our people should a future disease outbreak emerge."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending frameworks previously established via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its information, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how subsequent collaboration might be structured in a manner that honours the independence and dignity of each country."
Health Experts Response
Medical experts stated it recognised the government's concerns, but suggested that negotiations need to persist given that a large portion of the country's HIV programmes relied on foreign aid.
"Where technical issues exist, such as those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," the group said.
This impasse highlights the complex challenges between accepting much-needed international aid and protecting a country's data in an ever more data-driven world.